Fragile Gene
AP-2α
AP-2γ
TFAP2A
TFAP2C
WWOX
bladder cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
10
2020
accepted:
18
01
2021
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
16
3
2021
Statut:
epublish
Résumé
The presence of common fragile sites is associated with no-accidental chromosomal instability which occurs prior to carcinogenesis. The RT-112 cell line (grade II bladder cancer) was subjected to two stable lentiviral transductions. Overall, this resulted in six variants to investigate distinct WWOX, AP-2α, or AP-2γ function as well as WWOX in collaboration with a particular transcription factor. Cellular models were examined with immunocytochemical staining and in terms of differences in biological processes using assays investigating cell viability, proliferation, apoptosis, adhesion, clonogenicity, migration, activity of metalloproteinases and 3D culture growth. WWOX overexpression increased apoptosis but decreased cell viability, migration and large spatial colonies. AP-2α overexpression decreased tumor cell viability, migratory potential, matrix metalloproteinase-2 activity and clonogenicity. AP-2γ overexpression decreased matrix metalloproteinase-2 activity but increased wound healing, adhesion, clonogenicity and spatial colony formation. WWOX and AP-2α overexpression induced apoptosis but decreased cell viability, adhesion, matrix metalloproteinase-2 activity, overall number of cultured colonies and migration rate. WWOX and AP-2γ overexpression decreased tumor cell viability, proliferation potential, adhesion, clonogenicity and the ability to create spatial structures, but also increased apoptosis or migration rate. Co-overexpression of WWOX with AP-2α or WWOX with AP-2γ resulted in a net anti-tumor effect. However, considering this research findings and the difference between AP-2α and AP-2γ, we suggest that this similarity is due to a divergent behavior of WWOX.
Identifiants
pubmed: 33718178
doi: 10.3389/fonc.2021.621060
pmc: PMC7947623
doi:
Types de publication
Journal Article
Langues
eng
Pagination
621060Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2021 Kołat, Kałuzińska and Płuciennik.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Cancer Res. 2007 Oct 15;13(20):6115-21
pubmed: 17947476
F1000Res. 2016 Dec 15;5:
pubmed: 28232860
Oncogene. 2014 Jul 10;33(28):3707-16
pubmed: 23975430
Future Oncol. 2010 Feb;6(2):249-59
pubmed: 20146584
Cell Death Dis. 2018 May 3;9(5):511
pubmed: 29724996
J Exp Clin Cancer Res. 2018 Feb 13;37(1):27
pubmed: 29439714
Sci Rep. 2019 Jan 30;9(1):950
pubmed: 30700826
Int J Mol Sci. 2019 Jun 05;20(11):
pubmed: 31195692
Eur Rev Med Pharmacol Sci. 2020 Feb;24(3):1041-1053
pubmed: 32096174
BMC Cancer. 2011 Apr 14;11:135
pubmed: 21489314
J Cancer. 2016 Aug 7;7(12):1740-1746
pubmed: 27698912
Tumour Biol. 2012 Aug;33(4):985-94
pubmed: 22252525
J Biol Chem. 2002 Nov 22;277(47):45028-33
pubmed: 12226108
Genes Chromosomes Cancer. 2015 Dec;54(12):745-61
pubmed: 26390919
Cancer Cell. 2002 Feb;1(1):89-97
pubmed: 12086891
Clin Cancer Res. 2005 Jan 1;11(1):267-72
pubmed: 15671555
Int J Mol Med. 2016 Dec;38(6):1850-1856
pubmed: 27840941
Oncogene. 1996 Oct 17;13(8):1701-7
pubmed: 8895516
Biol Direct. 2017 Apr 17;12(1):8
pubmed: 28412966
Cancers (Basel). 2017 Jul 29;9(8):
pubmed: 28758926
Nature. 2003 May 22;423(6938):448-52
pubmed: 12717451
Oncogene. 2005 Jan 20;24(4):637-49
pubmed: 15580298
Cytogenet Genome Res. 2016;150(3-4):208-216
pubmed: 28199992
Biol Reprod. 2010 Jan;82(1):214-23
pubmed: 19776388
JCI Insight. 2019 Jan 24;4(2):
pubmed: 30674726
Oncol Rep. 2013 Jun;29(6):2154-62
pubmed: 23525648
Oncol Lett. 2014 Nov;8(5):2291-2297
pubmed: 25295115
Pathol Res Pract. 2013 Feb 15;209(2):99-104
pubmed: 23333248
Oncol Lett. 2015 Apr;9(4):1614-1620
pubmed: 25789010
Nat Mater. 2020 Feb;19(2):227-238
pubmed: 31659294
Cancer Res. 2005 Oct 1;65(19):8628-34
pubmed: 16204029
Gene. 2000 Dec 30;260(1-2):1-12
pubmed: 11137286
Oncogene. 2004 Jun 24;23(29):5049-55
pubmed: 15064722
Zhonghua Yi Xue Za Zhi. 2016 Nov 1;96(40):3227-3231
pubmed: 27852389
Neoplasma. 2012;59(2):216-23
pubmed: 22248280
Cancer Manag Res. 2019 May 23;11:4677-4690
pubmed: 31213893
Appl Immunohistochem Mol Morphol. 2016 May-Jun;24(5):345-54
pubmed: 25906126
J Biol Chem. 2003 Dec 26;278(52):52093-101
pubmed: 14551210
Cancer Res. 2010 Jul 1;70(13):5577-86
pubmed: 20530675
Stem Cell Reports. 2016 Dec 13;7(6):1140-1151
pubmed: 27916539
Onco Targets Ther. 2019 Jul 17;12:5701-5711
pubmed: 31410017
Genome Res. 2014 May;24(5):869-84
pubmed: 24515121
Histopathology. 2008 Jun;52(7):831-9
pubmed: 18452537
PLoS One. 2015 Aug 24;10(8):e0136356
pubmed: 26302329
Mol Oncol. 2020 Dec 2;:
pubmed: 33269540
PLoS Comput Biol. 2013 Oct;9(10):e1003286
pubmed: 24250280
Front Cell Neurosci. 2019 Aug 30;13:391
pubmed: 31543760
Pigment Cell Res. 2001 Apr;14(2):78-85
pubmed: 11310795
Cell Biosci. 2020 Mar 5;10:29
pubmed: 32166014
Int J Oncol. 2015;46(6):2639-48
pubmed: 25892250
Cell Biochem Biophys. 2015 Nov;73(2):417-425
pubmed: 27352332
Int J Mol Med. 2013 May;31(5):1139-47
pubmed: 23525362
Biotechniques. 2009 Apr;46(4):265-74
pubmed: 19450233
Nature. 2010 Feb 18;463(7283):893-8
pubmed: 20164919
Biol Res. 2019 Jul 11;52(1):35
pubmed: 31296259
Development. 2009 Feb;136(4):615-25
pubmed: 19144722
Tumour Biol. 2014 Sep;35(9):9291-301
pubmed: 24938873
BMC Cancer. 2006 Jan 13;6:12
pubmed: 16412233
J Biol Chem. 2008 Aug 1;283(31):21629-39
pubmed: 18487609
Int J Cancer. 2011 Mar 15;128(6):1327-34
pubmed: 20473948
Oncogene. 2001 Aug 16;20(36):5005-14
pubmed: 11526485
Mol Cell Endocrinol. 2014 Jan 25;382(1):642-651
pubmed: 23933151
Biosci Rep. 2019 Mar 15;39(3):
pubmed: 30824562
Cell Cycle. 2019 Jun;18(11):1177-1186
pubmed: 31075076
Oncol Rep. 2014 Oct;32(4):1362-8
pubmed: 25051421
Methods Mol Biol. 2009;522:203-10
pubmed: 19247616
Arch Toxicol. 2008 May;82(5):273-99
pubmed: 18443763
Genes Chromosomes Cancer. 2010 Sep;49(9):819-30
pubmed: 20607706
Exp Mol Med. 2016 Nov 25;48(11):e273
pubmed: 27885255
Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):744-7
pubmed: 7846046
Nat Med. 1999 Jun;5(6):662-8
pubmed: 10371505
Oncogenesis. 2019 Nov 26;8(12):69
pubmed: 31772149
Cancer Res. 2015 Jan 1;75(1):11-5
pubmed: 25524900
Front Oncol. 2018 Aug 28;8:345
pubmed: 30211123
Sci Rep. 2019 Apr 3;9(1):5564
pubmed: 30944375
Int J Mol Med. 2014 Sep;34(3):804-9
pubmed: 24968878
Int J Oncol. 2016 Mar;48(3):1125-34
pubmed: 26780928
Cold Spring Harb Perspect Biol. 2012 Jan 01;4(1):a004903
pubmed: 21937732
Int J Mol Med. 2016 Mar;37(3):807-15
pubmed: 26820701
Exp Biol Med (Maywood). 2015 Mar;240(3):329-37
pubmed: 25488911
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15611-6
pubmed: 16223882
J Biol Chem. 2005 Dec 30;280(52):43100-8
pubmed: 16219768
BJU Int. 2009 Dec;104(11):1774-9
pubmed: 19624598
Cytogenet Genome Res. 2016;150(3-4):217-226
pubmed: 28142148
Acta Biochim Biophys Sin (Shanghai). 2011 Nov;43(11):840-8
pubmed: 21968416
World J Gastroenterol. 2012 Mar 7;18(9):979-85
pubmed: 22408359
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Oncogene. 2007 Oct 18;26(48):6905-14
pubmed: 17486069
Exp Biol Med (Maywood). 2018 Sep;243(13):1066-1073
pubmed: 30335523
Cell Death Discov. 2015 Aug 03;1:15003
pubmed: 27551439
J Cancer Res Clin Oncol. 2003 Apr;129(4):199-221
pubmed: 12707770
Gene. 2003 Jan 2;302(1-2):155-64
pubmed: 12527206
Cancer Res. 2004 Nov 15;64(22):8256-61
pubmed: 15548692
Cancer Res. 2019 Apr 15;79(8):1784-1798
pubmed: 30622118